Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as a solution for injection for intravenous use. It enhances magnetic resonance imaging in adult patients requiring detailed visualization of the liver, central nervous system, cardiovascular system, or whole‑body assessments.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The product complies with EU regulatory standards and is distributed under strict quality‑assured conditions. It is available for bulk procurement and supports imaging departments in delivering accurate diagnostic results.

Multihance (gadobenate dimeglumine) is used as a gadolinium‑based contrast agent to improve magnetic resonance imaging across several organ systems.

Liver MRI: provides high‑resolution images of hepatic vasculature and lesions, aiding detection and characterization. Central nervous system MRI: enhances visualization of brain and spinal cord structures, facilitating diagnosis of tumors, vascular malformations, and inflammatory disease. Cardiovascular MRI: improves delineation of cardiac chambers, vessels, and myocardial perfusion for functional and anatomical assessment. Whole‑body MRI: offers comprehensive contrast enhancement for systemic disease staging and metastasis evaluation.

Adverse reactions to Multihance are generally infrequent but can range from mild to severe.

Common Side Effects: - Nausea: mild nausea or vomiting shortly after injection. - Headache: transient headache during or after the procedure. - Injection site discomfort: pain or warmth at the site of administration. - Warm sensation: brief feeling of heat throughout the body.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis: a rare fibrotic disorder in patients with severe renal impairment. - Severe allergic reaction: anaphylaxis or bronchospasm requiring emergency treatment. - Cardiovascular collapse: hypotension or cardiac arrest in susceptible individuals. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before using Multihance, clinicians should observe several precautionary measures to minimise risk. - Renal function assessment: evaluate glomerular filtration rate to identify patients at risk of nephrogenic systemic fibrosis. - Pregnancy considerations: use only when benefits outweigh potential fetal risks, as the agent is category C. - Allergy screening: inquire about prior reactions to gadolinium‑based agents or iodinated contrast. - Concomitant nephrotoxic drugs: monitor renal status when patients receive agents such as aminoglycosides or NSAIDs. - Dosage guidance: follow the prescriber’s recommended volume based on body weight and imaging protocol. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with certain conditions or medications, requiring careful assessment.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): markedly increased risk of nephrogenic systemic fibrosis; avoid use. - Cumulative gadolinium exposure: avoid sequential use of multiple linear gadolinium agents within a short interval.

Moderate Interactions (Monitor Closely): - Loop diuretics: may enhance renal clearance changes; monitor renal function. - Nephrotoxic agents (e.g., aminoglycosides, NSAIDs): increase risk of renal injury; observe kidney parameters. - Iron chelators (e.g., deferoxamine): can alter gadolinium binding; watch for reduced efficacy.